Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAF237 versus placebo in drug-naive adults with type 2 diabetes and mild hyperglycemia
2004-000539-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LAF237 with Placebo (2 arms). Primary endpoint: HbA1c reduction at 52 weeks. Started Jul 2004; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000539-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000539-27.